This retrospective study evaluated the safety and efficacy of FDQ, a Chinese herbal decoction, in the treatment of patients with NCP. Clinical data showed an association between FDQ treatment and symptomatic improvement, as well as a shortened duration of hospitalization. Symptomatic improvement has also been observed in a separate study, which examined the use of FDQ to treat a big cluster infection in a special population (manuscript submitted for publication by Wang W and Fu B [unpublished data]), in which the most common COVID-19 related symptoms, such as cough and fever, improved or disappeared within 48 hours of FDQ administration. Additionally, FDQ treatment was well tolerated and was not associated with any serious adverse events during the study period. Some patients reported mild diarrhea or abdominal pain, which usually disappeared within 2–3 days.
Several studies have suggested that the risk of severe illness in patients with COVID-19 increases with age, with the highest risk in older adults [13, 14]. Consistent with the results of other studies [15, 16], we found that the duration of hospitalization increased with age, especially in patients who were not treated with FDQ. However, a similar trend was not observed in patients treated with FDQ who were aged ≥ 31 years. With FDQ treatment, the average length of hospital stay among patients aged ≥ 61 years was only 18.0 days, which did not significantly differ from that of 18.7 days in patients aged 31–60 years (P = 0.525), indicating the effectiveness of FDQ for treating NCP. However, the overall duration of hospitalization observed in this cohort study was longer than the median length of 10–13 days that has been reported previously [15]. This discrepancy may have been due to differences in the thresholds for hospitalization.
In addition, on Cox proportional-hazard model analysis, a higher estimated survival rate was observed in patients of all age groups who received FDQ treatment versus those who did not receive FDQ. Moreover, the effects of FDQ were more notable in elderly patients than in young patients, which is important to consider when establishing an effective therapeutic plan for the former patient population.
Recent studies have associated elevated CRP levels with poor outcomes [17, 18]. However, we did not find a correlation between high CRP levels and an increased risk of developing more severe disease in our study. This discrepancy may have been due to the limited sample size or the benefits of FDQ treatment.
Our study had some limitations because of its retrospective, observational design. First, we did not perform a randomized comparison; therefore, assignment of treatment and patient biases cannot be ruled out. Second, the study population only included patients within Xianning City, Hubei Province, China. Third, most cases were diagnosed in outpatient settings with limited documentation of medical information, resulting in inadequate laboratory data. Fourth, clinical features during the disease course were not available, and the data for some important COVID-19 biomarkers, such as interleukin-6 and D-dimer levels [16], were absent due to a shortage of laboratory supplies and medical staff. This prevented the monitoring of changes in results over time, along with other clinical indicators. Additionally, our findings were limited by the absence of knowledge regarding confounding factors, such as the prevalence of chronic health conditions. Therefore, other unrecognized potential factors may have influenced our results. Nonetheless, a significantly shortened length of hospital stay and symptomatic improvement after FDQ treatment can be considered as extremely good surrogate indicators of both drug efficacy and safety in clinical practice.
To the best of our knowledge, this is the first large-scale cohort study that specifically examined the use of a traditional Chinese medicine in the treatment of COVID-19, although traditional Chinese medicine has been widely applied in China with satisfactory results. Despite the limitations of this study, FDQ appears to be an effective and safe treatment option for patients with NCP, even in the elderly. Indeed, because of its remarkable clinical efficacy, FDQ has been widely used by outpatients at home and in senior care and mental health centers. Xianning City achieved a 98.21% cure rate in treating COVID-19 patients [19, 20]. In addition, FDQ is inexpensive and easy to administer (drinking twice daily), and only minimal side effects have been observed as a result of its use. This observational study suggests that the use of FDQ may provide clinical benefit, although these findings require validation by randomized controlled trials in the future.